For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230713:nRSM9754Fa&default-theme=true
RNS Number : 9754F Syncona Limited 13 July 2023
Syncona Limited
Issue of shares pursuant to long-term incentive scheme and PDMR dealings
13 July 2023
Syncona Ltd (the "Company"), a leading healthcare company focused on creating,
building and scaling a portfolio of global leaders in life science, today
announces that a total of 2,477,342 new ordinary shares (representing 0.37%
of the Company's existing issued ordinary shares) will be issued in
satisfaction of realisations under the Company's long term incentive scheme.
The new ordinary shares, when issued, will rank pari passu with the existing
issued ordinary shares of the Company. In accordance with the rules of the
incentive scheme, the number of ordinary shares to be issued has been
calculated using the closing mid-market price on 12 July, 2023, £1.548.
In accordance with the rules of the incentive scheme, ordinary shares
delivered on realisation may not be sold or transferred by the recipient for a
period of one year following the realisation date.
The issue of shares include the following shares to be issued to senior
members of the Syncona Investment Management Limited (SIML) leadership team:
Name SIML Title No. of shares to be issued
Martin Murphy Chair 1,117,873
Chris Hollowood Chief Executive Officer 719,421
Application will be made to the Financial Conduct Authority for the shares to
be admitted to the Official List, and to the London Stock Exchange for the
shares to be admitted to trading and it is expected that dealings will
commence in the new ordinary shares on 19 July 2023.
Following admission, the Company will have 671,806,666 ordinary shares in
issue and the total number of voting rights in the Company will
be 671,806,666. The Company does not hold any ordinary shares in
treasury. This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change in their interests in, the Company under the FCA's
Disclosure and Transparency Rules.
Notification of transactions by Persons Discharging Managerial
Responsibilities ("PDMRs") are set out below.
ENDS
Enquiries
Syncona Ltd
Annabel Clark / Fergus Witt
Tel: +44 (0) 20 3981 7940
About Syncona
Syncona's purpose is to invest to extend and enhance human life. We do this by
creating and building companies to deliver transformational treatments to
patients in areas of high unmet need.
Our strategy is to create, build and scale companies around exceptional
science to create a diversified portfolio of 20-25 globally leading life
science businesses, across development stage, modality and therapeutic areas,
for the benefit of all our stakeholders. We focus on developing treatments for
patients by working in close partnership with world-class academic founders
and management teams. Our balance sheet underpins our strategy enabling us to
take a long-term view as we look to improve the lives of patients with no or
poor treatment options, build sustainable life science companies and deliver
strong risk-adjusted returns to shareholders.
Copies of this press release and other corporate information can be found on
the company website at: www.synconaltd.com (http://www.synconaltd.com/)
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Martin Murphy
2. Reason for the notification
a) Position / status Chair, SIML
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Syncona Limited
b) LEI 213800X8MBI5VQITLW60
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary shares
GG00B8P59C08
b) Nature of the transaction Issue of shares pursuant to the Syncona long term incentive scheme
c) Price(s) and volume(s) Price(s) Volume(s)
£1.548 1,117,873
d) Aggregated information
Aggregated volume
Price N/A
e) Date of the transaction 13 July 2023
f) Place of the transaction Outside a trading venue
g) Currency GBP - British Pound
d)
Aggregated information
Aggregated volume
Price
N/A
e)
Date of the transaction
13 July 2023
f)
Place of the transaction
Outside a trading venue
g)
Currency
GBP - British Pound
1. Details of PDMR / person closely associated with them ("PCA")
a) Name Chris Hollowood
2. Reason for the notification
a) Position / status Chief Executive Officer, SIML
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Syncona Limited
b) LEI 213800X8MBI5VQITLW60
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary shares
GG00B8P59C08
b) Nature of the transaction Issue of shares pursuant to the Syncona long term incentive scheme
c) Price(s) and volume(s) Price(s) Volume(s)
£1.548 719,421
d) Aggregated information
Aggregated volume
Price N/A
e) Date of the transaction 13 July 2023
f) Place of the transaction Outside a trading venue
g) Currency GBP - British Pound
d)
Aggregated information
Aggregated volume
Price
N/A
e)
Date of the transaction
13 July 2023
f)
Place of the transaction
Outside a trading venue
g)
Currency
GBP - British Pound
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHRJMITMTTBBBJ